Paper describing the effect of Methotrexate and BAFF levels during TNF inhibitor treatment in RA patients. Work done within the ABIRISK project with SciCross contributing in the managements of clinical data and data analysis. Check out the full paper at: https://ard.bmj.com/content/77/10/1463.long
In a recent paper, published in Journal of Clinical Investigation Insight, we describe a number of factors that influence the risk of immunogenicity responses (anti drug antibodies, ADA) in Multiple Sclerosis patients treated with Interferon beta (IFN-β). We found that NOTCH2 expression on CD14+ cells and increased frequency of proinflammatory monocyte subsets can be used as baseline predictors of neutralizing ADA (nADA) in MS patients treated with IFN-β. Further investigation of NOTCH2 showed that nADA development was driven by a proinflammatory environment that triggered activation of the NOTCH2 signaling pathway prior to first IFN-β administration.
Check out the full paper.
In a collaboration with the University of Tübingen and Harvard Medical School we have published a paper on how to reduce immunogenicity and at the same time keep protein stability/function. The approach is based on multi-objective combinatorial optimisation and was tested on the C2 domain of Factor VIII. For the full paper, go to Population-specific design of de-immunized protein biotherapeutics.